English Українська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Pochinska M.V., Shevchuk M.I.

    PULSE PRESSURE CLASSES AND FREQUENCY OF USE OF SEPARATE GROUPS OF CARDIAC DRUGS IN PATIENTS BEFORE AND IN THE EARLY PERIOD AFTER PACING


    About the author: Pochinska M.V., Shevchuk M.I.
    Heading CLINICAL MEDICINE
    Type of article Scentific article
    Annotation Pulse pressure (PP), which is determined by the difference between systolic and diastolic arterial pressure, depends on the degree of tone of the arterial walls and the left ventricular (LV) pumping function. PP beyond physiological values (40-60 mm Hg) increases the risk of cardiovascular complications and overall mortality. Permanent pacing, which is used to treat patients with rhythm and conduction disorders, as well as chronic heart failure (CHF), requires modification of the drug therapy that, in turn, affects the change in PP. However, changes in the frequency of the appointment of the main groups of cardiac drugs in the classes of PP in patients in the early period after pacemaker implantation in the literature have not been studied. In the proposed manuscript, the frequency of appointment of individual groups of cardiologic drugs depending on the PP classes in the early period after pacemaker implantation in 220 patients (110 men and 110 women) at the age of 70 ± 9 years was studied. Among the indications for the cardiac pacing were atrioventricular blockade, His bundle branch block, syndrome of weakness of the sinus node, constant bradysystolic form of atrial fibrillation and dilated cardiomyopathy. Exclusion criteria were: age less than 40 years, presence of concomitant angina pectoris IV functional class (FC), CHF IV FC, stimulation of the right ventricular and / or LV less than 50% throughout the observation period. Medication therapy was represented by the following means: anticoagulants (warfarin, pradaxa, ksarelto), antiagregants (clopidogrel, acetylsalicylic acid), antiarrhythmic drugs (amiodarone); β-adrenoblockers (metoprolol, bisoprolol, nebivolol, carvedilol), diuretics (hydrochlorothiazide, furosemide, thorassemide), antagonists of Ca (amlodipine, nifedipine and verapamil), angiotensin-converting enzyme (ACE) inhibitors (enalapril, lysinopril, ramipril), angiotensin II receptor antagonists (ARA II) (losartan, candesartan). Patients were classified into five classes of PP: I - very low PP - less than 20 mm Hg, II - lower than 20 - less than 40 mm Hg, III - normal - 40 - 60 mm Hg, IV - high above 60 - less than 80 mm Hg, V - very high PP - more than 80 mm Hg. The frequency of appointment of the listed medicines in the early period after the pacemaker implantation in each PP class was determined. The results were processed after the database was created. Statistical processing was performed using Microsoft Excel (for nonparametric data: absolute (n, number) and relative (p, %) units). Statistical significance of differences between groups was determined by non-parametric U-Mann-Whitney. Expected result was determined by the level of reliability p <0,05. The study showed that permanent pacing does not reduce the need for patients in drug therapy, moreover, the frequency of appointment of antiarrhythmic drugs (amiodarone and β-adrenoblockers) and ARA II increases the greater the higher the initial grade of PP. In the early post-implantation period, an increase in the frequency of appointment of anticoagulants and antiplatelet agents in each class of PP is required. The frequency of the appointment of diuretics, antagonists of Ca and ACE inhibitors increases with the PP class but does not require any changes in the early post-implantation period. Patients with permanent pacemaker require careful selection of medication based on the PP class.
    Tags pacing, pulse pressure classes, drug therapy
    Bibliography
    • Davidovich I, Neapolitanskaya N. Vliyaniye razlichnykh rezhimov postoyannoy elektrokardiostimulyatsii na sutochnyi profil arterialnogo davleniya u lits s ishemicheskoy boleznyu serdtsa v sochetanii s gipertonicheskoy boleznyu. Dalnevostochnyi meditsinskiy zhurnal. 2012;(2):14-18. [in Russian]
    • Briet M, Boutouyrie P, Laurent S, London G. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney International. 2012; 82(4):388-400.
    • Christofaro D, Casonatto J, Vanderlei L, Cucato G, Dias R. Relationship between Resting Heart Rate, Blood Pressure and Pulse Pressure in Adolescents. Arquivos Brasileiros de Cardiologia. 2017; 108(5):405-410.
    • Derienko T, Volkov D, Lopin D, Yabluchanskyi M. Hypertension degree and frequency of adminiіtration of certain groups of cardiac drugs in patientі at the annual follow-up stage of pace-maker implantation. Міжнародний медичний журнал. 2017; 2(90):19–23.
    • Ellims A, Mariani J, Schlaich M. Restoration of blood pressure control with pacemaker implantation in a patient with bradycardia and resistant hypertension: A case report. International Journal of Cardiology. 2013; 167(2):e38-e40.
    • Grigoryan L, Pavlik V, Hyman D. Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. Journal of the American Society of Hypertension. 2013; 7(6):471-476.
    • Kolomytseva I. Functional class of chronic heart failure and supportive drug therapy in patients at the annual stage pacing/ I.N Kolomytseva. Canadian Journal of Education and Engineering. 2015; 2(12):569-578.
    • Schroeder C, Heusser K, Zoerner A, Großhennig A, Wenzel D, May M et al. Pacemaker Current Inhibition in Experimental Human Cardiac Sympathetic Activation: A Double-Blind, Randomized, Crossover Study. Clinical Pharmacology & Therapeutics. 2014; 95(6):601-607.
    • Shanina I, Volkov D. Frequency of detached cardiac drugs prescribing in patients of different classes QRS complex duration on the permanent pacing background. The Journal of V N Karazin Kharkiv National University, series "Medicine." 2014; 1108(27):33-37.
    • Torjesen A, Sigurthsson S, Westenberg J, Gotal J, Bell V, Aspelund T et al. Pulse Pressure Relation to Aortic and Left Ventricular Structure in the Age, Gene, Environment Susceptibility (AGES)-Reykjavik Study. Hypertension. 2014; 64(4): 756-761.
    • Tracy C, Epstein A, Darbar D, DiMarco J, Dunbar S, Estes N et al. 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2012; 126(14):1784-1800.
    Publication of the article «World of Medicine and Biology» №3(65), 2018 year, 115-118 pages, index UDK 616.12-089; 615.036.2
    DOI 10.26724/2079-8334-2018-3-65-115-118